Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3Recurrence 2Rectal Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1Colonic Neoplasms 1Alopecia 1

Interventions

Fluorouracil 218Leucovorin 201Oxaliplatin 191Irinotecan 148Bevacizumab 107Capecitabine 93Cetuximab 89Folfox protocol 54Chemotherapy, Adjuvant 34Panitumumab 30pembrolizumab 23Nivolumab 22Colonoscopy 22Gemcitabine 20Magnetic Resonance Spectroscopy 19Floxuridine 19IFL protocol 18Celecoxib 18Radiotherapy 17Neoadjuvant Therapy 17Early Intervention, Educational 17Drug Therapy 17Laparoscopy 14Cyclophosphamide 14Counseling 14trifluridine tipiracil drug combination 13regorafenib 13XELOX 13Exercise 13Erlotinib Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Colonic Neoplasms × Immunoconjugates × Clear all
NCT01605318 2024-01-24

Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

Gilead Sciences

Phase 1/2 Terminated
92 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡